Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis
IntroductionGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individuals with type 2 diabetes. However, the data of its...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1453297/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841547306995810304 |
|---|---|
| author | Raveena Kelkar Nishad A. Barve Rohan Kelkar Sanjeev Kharel Shalmi Khanapurkar Rukesh Yadav |
| author_facet | Raveena Kelkar Nishad A. Barve Rohan Kelkar Sanjeev Kharel Shalmi Khanapurkar Rukesh Yadav |
| author_sort | Raveena Kelkar |
| collection | DOAJ |
| description | IntroductionGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individuals with type 2 diabetes. However, the data of its efficacy in reducing cardiovascular events in individuals without type 2 diabetes is not as robust. We aim to update and conduct a systematic review and meta-analysis to assess the same.MethodsThe study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guideline. Researchers searched PubMed, EMBASE, and Clinicaltrails.gov for English literature from inception to 2024. Randomized Controlled trails enrolling adult participants (age ≥ 18 years) who are overweight or obese (BMI > 25 Kg/m2) with a comparison of all cardiovascular events between patients taking GLP1-RA and placebo were included. The analysis was done by Revman version 5.4.ResultsA total of 17 RCTs among 34,419 participants were included in the analysis. The pooled risk ratio from 17 studies illustrated that patients with GLP-1 RA had a significantly lower risk of cardiovascular events compared to patients who had a placebo (RR = 0.75; 95% confidence interval 0.64–0.89, p-value = 0.0008). Semaglutide was found to have a statistically significant greatest risk reduction than other drug types.ConclusionsThis meta-analysis found that GLP-1 RA significantly reduced all types of cardiovascular events in overweight and obese patients without diabetes. Semaglutide was found to be superior to others in CV event reductions. But still, the results of ongoing trials are needed.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=553048, PROSPERO (CRD42024553048). |
| format | Article |
| id | doaj-art-0600a3d9d53c4cff9a4723986102755e |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-0600a3d9d53c4cff9a4723986102755e2025-01-10T14:47:25ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2024-09-011110.3389/fcvm.2024.14532971453297Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysisRaveena Kelkar0Nishad A. Barve1Rohan Kelkar2Sanjeev Kharel3Shalmi Khanapurkar4Rukesh Yadav5Internal Medicine, Cleveland Clinic Akron General, Akron, OH, United StatesInternal Medicine, Cleveland Clinic Mercy, Canton, OH, United StatesDepartment of Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune, IndiaInternal Medicine, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, NepalInternal Medicine, Deenanath Mangeshkar Hospital, Pune, IndiaInternal Medicine, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, NepalIntroductionGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individuals with type 2 diabetes. However, the data of its efficacy in reducing cardiovascular events in individuals without type 2 diabetes is not as robust. We aim to update and conduct a systematic review and meta-analysis to assess the same.MethodsThe study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guideline. Researchers searched PubMed, EMBASE, and Clinicaltrails.gov for English literature from inception to 2024. Randomized Controlled trails enrolling adult participants (age ≥ 18 years) who are overweight or obese (BMI > 25 Kg/m2) with a comparison of all cardiovascular events between patients taking GLP1-RA and placebo were included. The analysis was done by Revman version 5.4.ResultsA total of 17 RCTs among 34,419 participants were included in the analysis. The pooled risk ratio from 17 studies illustrated that patients with GLP-1 RA had a significantly lower risk of cardiovascular events compared to patients who had a placebo (RR = 0.75; 95% confidence interval 0.64–0.89, p-value = 0.0008). Semaglutide was found to have a statistically significant greatest risk reduction than other drug types.ConclusionsThis meta-analysis found that GLP-1 RA significantly reduced all types of cardiovascular events in overweight and obese patients without diabetes. Semaglutide was found to be superior to others in CV event reductions. But still, the results of ongoing trials are needed.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=553048, PROSPERO (CRD42024553048).https://www.frontiersin.org/articles/10.3389/fcvm.2024.1453297/fullGLP-1 RAobesitycardiovascular eventnon-diabeticoverweight |
| spellingShingle | Raveena Kelkar Nishad A. Barve Rohan Kelkar Sanjeev Kharel Shalmi Khanapurkar Rukesh Yadav Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis Frontiers in Cardiovascular Medicine GLP-1 RA obesity cardiovascular event non-diabetic overweight |
| title | Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis |
| title_full | Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis |
| title_fullStr | Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis |
| title_full_unstemmed | Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis |
| title_short | Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis |
| title_sort | comparison of glucagon like peptide 1 receptor agonists vs placebo on any cardiovascular events in overweight or obese non diabetic patients a systematic review and meta analysis |
| topic | GLP-1 RA obesity cardiovascular event non-diabetic overweight |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1453297/full |
| work_keys_str_mv | AT raveenakelkar comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis AT nishadabarve comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis AT rohankelkar comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis AT sanjeevkharel comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis AT shalmikhanapurkar comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis AT rukeshyadav comparisonofglucagonlikepeptide1receptoragonistsvsplaceboonanycardiovasculareventsinoverweightorobesenondiabeticpatientsasystematicreviewandmetaanalysis |